Stocks Comparison
20/20 Biolabs vs Neogenomics: revenue, profit, margins and growth compared
20/20 Biolabs brought in $2M of revenue in fiscal 2025, Neogenomics $727.3M in fiscal 2025. Revenue changed by +16.7% at 20/20 Biolabs and +10.1% at Neogenomics on the year before, so 20/20 Biolabs grew faster. 20/20 Biolabs kept -182.8% of its revenue as net profit, Neogenomics -14.9%.
Side by side, latest fiscal year
| AIDX | NEO | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $2M | $727.3M |
| Revenue growth | +16.7% | +10.1% |
| Net income | -$3.7M | -$108M |
| Net margin | -182.8% | -14.9% |
| Free cash flow | n/a | -$21.8M |
| Free cash flow margin | n/a | -3.0% |
| Earnings per share (diluted) | -$0.76 | n/a |
| Cash | $1M | $159.6M |
| Debt | n/a | $341.9M |
| Price to earnings | n/a | n/a |
| Market value | $5.6M | $2.5B |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #542 of 646 · Health care | #171 of 646 · Health care |
Over the years
Questions about 20/20 Biolabs and Neogenomics
Which is bigger by revenue, 20/20 Biolabs or Neogenomics?
Neogenomics is bigger by revenue: $727.3M in fiscal 2025, against $2M for 20/20 Biolabs in fiscal 2025.
Which keeps more of its revenue as profit, 20/20 Biolabs or Neogenomics?
20/20 Biolabs had a net margin of -182.8% in fiscal 2025; Neogenomics had -14.9% in fiscal 2025.
Which grew revenue faster, 20/20 Biolabs or Neogenomics?
In their latest fiscal years revenue changed by +16.7% at 20/20 Biolabs and +10.1% at Neogenomics.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.